Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: A sub-analysis of the WHO 2013 global hepatitis policy survey

BMC Infectious Diseases

Volumn 14, Issue , 2014, Pages

  Spina, Alexander ^a   Eramova, Irina ^b   Lazarus, Jeffrey V ^c  

^a AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; BOCEPREVIR; ENTECAVIR; TELAPREVIR;

ARTICLE; AWARENESS; DRUG SELF ADMINISTRATION; DRUG USE; HEALTH CARE POLICY; HEALTH SURVEY; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; PRACTICE GUIDELINE; QUESTIONNAIRE; WORLD HEALTH ORGANIZATION; ATTITUDE TO HEALTH; COMPLICATION; EUROPE; GOVERNMENT; HEALTH CARE SURVEY; SUBSTANCE ABUSE; TRANSMISSION;

EUROPE; GOVERNMENT PROGRAMS; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HEPATITIS B; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; WORLD HEALTH ORGANIZATION;

EID: 84908367148     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-S6-S15     Document Type: Article

References (38)

1. Mahoney F, Kane M. Hepatitis B Vaccine. Vaccines 1999, Philadelphia: Saunders Company, Plotkin SA and Orenstein WA, 3.
2. Lee WM. Hepatitis B Virus Infection. N Engl J Med 1997, 337:1733-1745.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30:2212-2219.
5. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol Baltim Md 2013, 57:1333-1342.
6. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
7. World Health Organization | World Malaria Report 2012. Geneva, Switzerland., http://www.who.int/malaria/publications/world_malaria_report_2012/en/
8. World Health Organization | Global Tuberculosis Report 2012. Geneva, Switzerland., http://www.who.int/tb/publications/global_report/en/
9. UNAIDS | 2012 UNAIDS Report on the Global AIDS Epidemic. Geneva., http://www.unaids.org/en/resources/publications/2012/name,76121,en.asp
10. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
11. Poynard T, Yuen M-F, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003, 362:2095-2100.
12. WHO | Guidelines for the screening, care and treatment of persons with hepatitis C infection. , http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/
13. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, Gottardi AD, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ. Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clin Infect Dis 2013, 57(suppl 2):S129-S137.
14. Global Commission on Drug Policy | The Negative Impact of The War On Drugs On Public Health: The Hidden Hepatitis C Epidemic. Rio de Janeiro, Brazil., http://www.globalcommissionondrugs.org/hepatitis/
15. European Centre for Disease Prevention and Control | Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm, Sweden., http://ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=560
16. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583. 3285467, 21802134.
17. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2013, 1-17.
18. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A, Murray CJL, Vos T. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1564-1574.
19. European Monitoring Centre for Drugs and Drug Addiction | European Drug Report 2013: Trends and developments. Lisbon, Portugal., http://www.emcdda.europa.eu/publications/edr/trends-developments/2013
20. Hickson F, Latypov A, Reynolds L, Platt L, Hope V, Jolley E, Rhodes T. HIV in the European Region: Using Evidence to Strengthen Policy and Programs. 2013, 1-20. The World Bank.
21. World Health Organization Executive Board| Viral hepatitis report by the Secretariat. EB126/15. Geneva, Switzerland., http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_15-en.pdf
22. Ticau S-A, Octavia-Sarbu D, Sorin-Ivan C, Tanasecu CC, Cretu C, Tarabella M, Gierek A, Rosbach A, Carvalho MDG, Grossetete F, Paravanova A. Written Declaration submitted under Rule 123 of the Rules procedure on hepatitis B and C. 2013,
23. World Health Organization| Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. Geneva, Switzerland., http://www.who.int/csr/disease/hepatitis/Framework/en/
24. World Health Organization | Global policy report on the prevention and control of viral hepatitis. Geneva, Switzerland., http://www.who.int/csr/disease/hepatitis/global_report/en/
25. Country and Lending Groups | Data. , http://data.worldbank.org/about/country-classifications/country-and-lending-groups
26. World Health Organization | Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva, Switzerland., http://www.who.int/hiv/pub/guidelines/hepatitis/en/
27. Liang TJ, Ghany MG. Current and Future Therapies for Hepatitis C Virus Infection. N Engl J Med 2013, 368:1907-1917. 3893124, 23675659.
28. Kohli A, Sims Z, Nelson A. Combination oral hepatitis C antiviral therapy for 6 or 12 weeks: final results of the SYNERGY trial. 2014, Boston.
29. Lai C-L, Yuen M-F. Chronic Hepatitis B - New Goals, New Treatment. N Engl J Med 2008, 359:2488-2491.
30. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection Drug Use and Hepatitis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention. Clin Infect Dis 2013, 57(suppl 2):S32-S38. 3722077, 23884063.
31. Treloar C, Rance J, Backmund M. Understanding Barriers to Hepatitis C Virus Care and Stigmatization From a Social Perspective. Clin Infect Dis 2013, 57(suppl 2):S51-S55.
32. De Vos AS, Kretzschmar MEE. The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users. J Theor Biol 2013, 333:126-134.
33. Des Jarlais DC, McKnight C, Arasteh K, Feelemyer J, Perlman DC, Hagan H, Cooper HLF. Transitions from injecting to non-injecting drug use: Potential protection against HCV infection. J Subst Abuse Treat 2013,
34. Bruggmann P, Litwin AH. Models of Care for the Management of Hepatitis C Virus Among People Who Inject Drugs: One Size Does Not Fit All. Clin Infect Dis 2013, 57(suppl 2):S56-S61.
35. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J 2013, 10:7. 3686576, 23651646.
36. Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatol Baltim Md 2009, 50:743-751.
37. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007, 147:460-469.
38. European Centre for Disease Prevention and Control | Hepatitis B and C surveillance report 2006-2011. Stockholm, Sweden., http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?ID=877&List=4f55ad51%2D4aed%2D4d32%2Db960%2Daf70113dbb90